CN Patent

CN100378107C — 唑并嘧啶和呋喃并嘧啶化合物以及它们作为抗肿瘤药物的用途

Assigned to Novartis AG · Expires 2008-04-02 · 18y expired

What this patent protects

本发明涉及可药用的式I化合物，其中各基团具有说明书中给出的含义。式I化合物可用于对抗肿瘤疾病。

USPTO Abstract

本发明涉及可药用的式I化合物，其中各基团具有说明书中给出的含义。式I化合物可用于对抗肿瘤疾病。

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: CN100378107C
Jurisdiction: CN
Classification: —
Expires: 2008-04-02
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.